Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 11:10:101.
doi: 10.3389/fonc.2020.00101. eCollection 2020.

Preclinical Models of Malignant Mesothelioma

Affiliations
Review

Preclinical Models of Malignant Mesothelioma

Joseph R Testa et al. Front Oncol. .

Abstract

Rodent models of malignant mesothelioma help facilitate the understanding of the biology of this highly lethal cancer and to develop and test new interventions. Introducing the same genetic lesions as found in human mesothelioma in mice results in tumors that show close resemblance with the human disease counterpart. This includes the extensive inflammatory responses that characterize human malignant mesothelioma. The relatively fast development of mesothelioma in mice when the appropriate combination of lesions is introduced, with or without exposure to asbestos, make the autochthonous models particularly useful for testing new treatment strategies in an immunocompetent setting, whereas Patient-Derived Xenograft models are particularly useful to assess effects of inter- and intra-tumor heterogeneity and human-specific features of mesothelioma. It is to be expected that new insights obtained by studying these experimental systems will lead to new more effective treatments for this devastating disease.

Keywords: conditional tumor suppressor gene knockout/oncogene mouse models; genetic driver lesions; in vivo asbestos carcinogenesis; malignant mesothelioma; mesothelioma inflammatory phenotype; patient-derived xenograft models of mesothelioma; preclinical rodent models.

PubMed Disclaimer

References

    1. Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, et al. . Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort [version 3]. F1000Res. (2018) 7:1184. 10.12688/f1000research.15512.2 - DOI - PMC - PubMed
    1. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, et al. . p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. (1994) 54:5547–5551. - PubMed
    1. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. (1995) 11:511–5. - PubMed
    1. Bianchi AB, Mitsunaga S-I, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. . High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA. (1995) 92:10854–8. 10.1073/pnas.92.24.10854 - DOI - PMC - PubMed
    1. Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. (1995) 55:1227–31. - PubMed

LinkOut - more resources